"10.1371_journal.pone.0059694","plos one","2013-03-19T00:00:00Z","Vilija G Jokubaitis; Tim Spelman; Jeannette Lechner-Scott; Michael Barnett; Cameron Shaw; Steve Vucic; Danny Liew; Helmut Butzkueven; Mark Slee; on behalf of the Australian MSBase Study Group","Melbourne Brain Centre (RMH), Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia; Department of Neurology, Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Neurology, John Hunter Hospital, Newcastle, New South Wales, Australia; Hunter Medical Research Institute, University of Newcastle, Newcastle New South Wales, Australia; Brain Mind Research Institute, Sydney, New South Wales, Australia; Department of Neuroscience, Geelong Hospital, Geelong, Victoria, Australia; Department of Neurology, Westmead Hospital, Westmead, New South Wales, Australia; Department of Neurology, Box Hill Hospital, Monash University, Box Hill, Victoria, Australia; Flinders University and Medical Centre, Adelaide, South Australia, Australia","Conceived and designed the experiments: HB VJ. Performed the experiments: VJ TS. Analyzed the data: VJ TS HB MS DL. Contributed reagents/materials/analysis tools: HB JLS MB MS CS SV. Wrote the paper: VJ MS HB DL JLS SV MB TS CS.","Dr Jokubaitis reports no disclosures. Dr Spelman has received a travel grant from Novartis Australia. Dr Lechner-Scotts institution receives non-directed funding as well as honoraria for presentations and membership on advisory boards from CSL, Genzyme, Biogen Idec, Bayer Health Care, Merck Serono and Novartis Australia. Dr Barnett has received research support and/or honoraria from Bayer Schering, Biogen Idec, Merck Serono, Novartis Pharma, Sanofi and Teva. Dr Shaw reports no disclosures. Dr Vucic serves on the scientific advisory board from Novartis Pharma, Merck Serono Australia and Bayer Schering Australia. Dr Vucic serves as a medical consultant for Merck Serono Australia. Dr Liew has received honoraria from Novartis and Sanofi. Dr Butzkueven has served on scientific advisory boards for Biogen Idec, Novartis and Sanofi and has received conference travel support from Novartis, Biogen Idec and Sanofi. He serves on steering committees for trials conducted by Merck Serono, Biogen Idec and Novartis. Dr Butzkueven has received research support from Merck Serono, Novartis and Biogen Idec in his capacity as honorary chair of the MSBase Foundation. He is on the editorial board of Multiple Sclerosis International. Dr Slee reports participating in advisory boards for Sanofi, Merck Serono, Biogen Idec, Novartis Pharma and Bayer Schering. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","03","Vilija G Jokubaitis","VGJ",10,TRUE,2,2,5,9,TRUE,TRUE,FALSE,0,NA,FALSE
